1. Home
  2. NAC vs DFTX Comparison

NAC vs DFTX Comparison

Compare NAC & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen California Quality Municipal Income Fund

NAC

Nuveen California Quality Municipal Income Fund

HOLD

Current Price

$11.65

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$18.89

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NAC
DFTX
Founded
1998
N/A
Country
France
United States
Employees
N/A
N/A
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NAC
DFTX
Price
$11.65
$18.89
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$40.25
AVG Volume (30 Days)
614.5K
1.6M
Earning Date
01-01-0001
05-04-2026
Dividend Yield
4.33%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.35
$14.62
52 Week High
$12.25
$19.67

Technical Indicators

Market Signals
Indicator
NAC
DFTX
Relative Strength Index (RSI) 42.78 56.78
Support Level $11.22 $16.26
Resistance Level $11.64 $19.55
Average True Range (ATR) 0.11 1.01
MACD -0.04 -0.02
Stochastic Oscillator 41.67 69.69

Price Performance

Historical Comparison
NAC
DFTX

About NAC Nuveen California Quality Municipal Income Fund

Nuveen California Quality Municipal Income Fund is a closed-end fixed income mutual fund that prominently invests in tax-exempt municipal bonds from California. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes. Its portfolio mainly includes investment-grade municipal securities of California. The fund targets various sectors such as healthcare, utilities, transportation, and consumer staples.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: